DOCSLIB.ORG

Fgr and Hck Neutrophils Requires the Src Family Kinases Adhesion-Dependent Degranulation Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fgr and Hck Neutrophils Requires the Src Family Kinases Adhesion-Dependent Degranulation Of Adhesion-Dependent Degranulation of Neutrophils Requires the Src Family Kinases Fgr and Hck This information is current as Attila Mócsai, Erzsébet Ligeti, Clifford A. Lowell and of September 25, 2021. Giorgio Berton J Immunol 1999; 162:1120-1126; ; http://www.jimmunol.org/content/162/2/1120 Downloaded from References This article cites 36 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/162/2/1120.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Adhesion-Dependent Degranulation of Neutrophils Requires the Src Family Kinases Fgr and Hck1 Attila Mo´csai,2*† Erzse´bet Ligeti,† Clifford A. Lowell,‡ and Giorgio Berton3* Polymorphonuclear neutrophils (PMN) adherent to integrin ligands respond to inflammatory mediators by reorganizing their cytoskeleton and releasing reactive oxygen intermediates. As Src family tyrosine kinases are implicated in these responses, we investigated their possible role in regulating degranulation. Human PMN incubated on fibrinogen released lactoferrin in response to TNF-a and this response was inhibited by PP1, a Src family tyrosine kinase inhibitor. This drug had no effect on lactoferrin secretion induced by PMA, an adhesion-independent agonist of PMN degranulation. However, PP1 blocked secretion in PMN plated on plain tissue culture plastic, a surface inducing PMN spreading in the absence of any stimulus. Double knockout hck2/2fgr2/2 PMN adherent to collagen or fibrinogen failed to release lactoferrin in response to TNF-a but responded to PMA 2/2 2/2 as wild-type PMN. Degranulation induced by spreading over tissue culture plastic was also defective in hck fgr PMN. Downloaded from Defective adhesion-dependent degranulation required the absence of both kinases, because single knockout fgr2/2 or hck2/2 PMN responded as wild-type cells. Analysis of lactoferrin secretion in hck2/2fgr2/2 or PP1-treated, suspended PMN showed that Src kinases are not implicated in degranulation dependent on activation of protein kinase C or increase in intracellular free Ca21 but may play a role in the response to FMLP of cytochalasin B-treated PMN. These findings identify a role for Src family kinases in a signaling pathway leading to granule-plasma membrane fusion and suggest that Fgr and Hck would be targets for pharmaco- logical control of adhesion-dependent degranulation in the inflammatory site. The Journal of Immunology, 1999, 162: 1120–1126. http://www.jimmunol.org/ olymorphonuclear neutrophils (PMN)4 adherent to extra- hesion and spreading of PMN are tightly coupled to an increase in cellular matrix proteins or endothelial counterreceptors re- tyrosine phosphorylation of several proteins, and tyrosine kinase P spond to inflammatory mediators, such as cytokines and inhibitors block adhesion-dependent generation of ROI by PMN chemoattractants, releasing reactive oxygen intermediates (ROI) (7, 8). The Src family tyrosine kinases Fgr, Hck, and Lyn, as well and granule constituents (1–5). These secretory responses are as p72syk, have been recently implicated in signaling from adhe- tightly coupled with a rearrangement of the cytoskeleton that dic- sion receptors (16–19). tates spreading of the cell over the adhesive surface (5–8). Dif- Signals involved in triggering degranulation by adherent PMN ferent adhesion receptors have been implicated in induction of are poorly understood. The evidence that protein tyrosine phos- by guest on September 25, 2021 b b PMN responses. For example, both 2 and 3 integrins have been phorylation (7, 16) and the Src family kinases Fgr and Hck (18) demonstrated to regulate PMN responses (2, 3, 6, 9–11). The re- play a critical role in ROI generation prompted us to investigate lease of ROI and degranulation in the context of PMN-endothelial whether adhesion-dependent degranulation is also regulated by the cell interactions plays a central role in the development of inflam- same signaling pathways. In this report, we show that adhesion- matory reactions and certainly contributes to tissue damage asso- dependent release of lactoferrin is blocked by a newly described ciated with inflammation (12, 13). tyrosine kinase inhibitor the effect of which has been reported to be In the last few years, a great progress has been made in the selective for Src family tyrosine kinases (20). Investigations with understanding of signaling from adhesion receptors (14, 15). Ad- PMN isolated from mice with the double deficiency of Fgr and Hck allowed us to demonstrate that these kinases play an essential role in signaling for adhesion-dependent degranulation. These re- † *Institute of General Pathology, University of Verona, Verona, Italy; Department of sults provide the first direct evidence that Src family kinases func- Physiology and Laboratory of Cellular and Molecular Physiology, Semmelweis Uni- versity of Medicine, Budapest, Hungary; and ‡Department of Laboratory Medicine, tion in a signaling pathway leading to granule-plasma membrane University of California, San Francisco, CA 94143 fusion. Received for publication March 26, 1998. Accepted for publication October 6, 1998. The costs of publication of this article were defrayed in part by the payment of page Materials and Methods charges. This article must therefore be hereby marked advertisement in accordance PMN isolation with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work was supported by grants from the Italian Association for Cancer Research Human PMN were isolated from buffy coats of healthy volunteers as pre- and Minister of University and Scientific Research of Italy/University of Verona viously described (9, 16). Wild-type (C57BL/6), p59/61hck,orp58c-fgr- (Research Program: Inflammation: Biology and Clinic) to G.B.; National Institutes of deficient single knockout mice and double knockout mice deficient in both Health Grants DK 50267 and HL54476 to C.A.L.; and grants from the Hungarian p59/61hck and p58c-fgr were described previously (21). Bone marrow of National Research Fund (OTKA) and the Swiss National Science Foundation 6–12-wk-old mice of both sexes were used in this study. Murine PMN (7UNPJ048717) to E.L. were isolated essentially as described (18) except that a simplified three- 2 Recipient of a short term fellowship from the European Molecular Biology layer gradient was utilized to separate neutrophils from other bone marrow Organization. cells (i.e., bone marrow cells suspended in Ca21-/Mg21-free HBSS sup- 3 Address correspondence and reprint requests to Dr. Giorgio Berton, Istituto di Pa- plemented with 0.1% BSA were layered on the top of a 62/81% two-layer tologia Generale, Universita`di Verona, Strada Le Grazie, 37134 Verona, Italy. E-mail Percoll (Pharmacia, Uppsala, Sweden) gradient, and after centrifugation, address: [email protected] PMN were harvested from the 62/81% interface). At the end of the prep- 4 Abbreviations used in this paper: PMN, polymorphonuclear neutrophils; ROI, aration, PMN were suspended in ice-cold HBSS containing 0.5 mM CaCl2, reactive oxygen intermediates; TNF, TNF-a; PKC, protein kinase C; CB, 1 mM MgCl2,and5mMD-glucose (HBSS) and kept in ice until use. For 1 cytochalasin B. experiments in which the Mg2 dependence of the PMN response was Copyright © 1999 by The American Association of Immunologists 0022-1767/99/$02.00 The Journal of Immunology 1121 investigated, cells were isolated as above described but resuspended in 21 21 Results Ca /Mg -free HBSS supplemented with 5 mM EDTA and, after 10 min TNF-stimulated lactoferrin release by adherent human and of incubation, washed and suspended in HBSS either with or without 1 mM Mg21 (17). murine PMN is blocked by the tyrosine kinase inhibitor PP1 Human adherent PMN can be stimulated to mobilize lactoferrin- Coating of tissue culture plastic plates with proteins containing specific granules in response to granulocyte-macro- Flat bottom polystyrene tissue culture plates with 96 wells (Greiner, Frick- phage-CSF, FMLP, or the Ca21 ionophore A23187 (5). As shown enhausen, Germany) were left untreated or were covered with rat collagen, in Fig. 1A, TNF is also an effective agonist of lactoferrin secretion human fibrinogen, or FCS as described (18). After coating, the plates were washed once with PBS and once with HBSS. in adherent human PMN. As previously reported with other stimuli (5), TNF-induced degranulation by adherent PMN is delayed in its Cell stimulation onset and prolonged up to 60 min of incubation (Fig. 1A). In ac- Human and murine PMN were washed at 4°C and resuspended in ice-cold cord with previous studies (4, 23–25), we could not detect release HBSS at 1 3 106 or 2 3 106 cells/ml, respectively. For adhesion assays, of the primary granule marker b-glucuronidase in response to TNF cell suspensions (100 ml/well), added or not with 10 mM PP1 (Calbiochem- (data not shown). Additionally, we also found that the response to Novabiochem Int., La Jolla, CA) were dispensed in protein-coated plates TNF depended on adhesion (25, 26), since suspended PMN failed and prewarmed for 10 min at 37°C before addition of 20 ng/ml human or murine TNF-a (TNF, Peprotech, London, U.K.), 100 ng/ml PMA (Sigma, to release lactoferrin following TNF stimulation while such cells St.
Load more

Recommended publications
  • Regulation of the Src Family Kinases by Csk Masato Okada
    Int. J. Biol. Sci. 2012, 8 1385 Ivyspring International Publisher International Journal of Biological Sciences 2012; 8(10):1385-1397. doi: 10.7150/ijbs.5141 Review Regulation of the Src Family Kinases by Csk Masato Okada Department of Oncogene Research, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, JAPAN. Corresponding author: TEL: 81-6-6879-8297 FAX: 81-6-6879-8298, E-mail: [email protected]. © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.08.31; Accepted: 2012.10.01; Published: 2012.11.01 Abstract The non-receptor tyrosine kinase Csk serves as an indispensable negative regulator of the Src family tyrosine kinases (SFKs) by specifically phosphorylating the negative regulatory site of SFKs, thereby suppressing their oncogenic potential. Csk is primarily regulated through its SH2 domain, which is required for membrane translocation of Csk via binding to scaffold proteins such as Cbp/PAG1. The binding of scaffolds to the SH2 domain can also upregulate Csk kinase activity. These regulatory features have been elucidated by analyses of Csk structure at the atomic levels. Although Csk itself may not be mutated in human cancers, perturbation of the regulatory system consisting of Csk, Cbp/PAG1, or other scaffolds, and certain tyrosine phosphatases may explain the upregulation of SFKs frequently observed in human cancers. This review focuses on the molecular bases for the function, structure, and regulation of Csk as a unique regulatory tyrosine kinase for SFKs.
    [Show full text]
  • Review Tec Kinases: a Family with Multiple Roles in Immunity
    Immunity, Vol. 12, 373±382, April, 2000, Copyright 2000 by Cell Press Tec Kinases: A Family Review with Multiple Roles in Immunity Wen-Chin Yang,*³§ Yves Collette,*³ inositol phosphates, but they are thought to be relevant Jacques A. NuneÁ s,*³ and Daniel Olive*² for binding of PtdIns lipids to the same sites. In most *INSERM U119 cases, PH domains bind preferentially to PtdIns (4,5)P2 Universite de la Me diterrane e and inositol (1,4,5) P3 (Ins (1,4,5) P3). However, the Btk 13009 Marseille PH domain binds PtdIns (3,4,5)P3 and Ins (1, 3, 4, 5)P4 France the tightest. PtdIns (3, 4, 5)P3, one of the products of the action of PI3K, is thought to act as a second messen- ger to recruit regulatory proteins to the plasma mem- brane via their PH domains (see below). Many of the Antigen receptors on T, B, and mast cells are multimo- mutations in Btk that lead to XLA are point mutations lecular complexes that are activated by interactions with that cluster at one end of the PH domain and could be external signals. These signals are then transmitted to predicted to impair binding to Ins (3,4,5)P (for review regulate gene expression and posttranscriptional modi- 3 see Satterthwaite et al., 1998a) (Figure 1b). Similarly, fications. Nonreceptor tyrosine kinases (NRTK) are key CBA/N xid mice carry an R28C mutation in the Btk PH players that relay and integrate these signals. NRTK are domain. The recent structure of the PH domain from divided into distinct families defined by a prototypic Btk complexed with Ins (1,3,4,5)P4 provides an explana- member: Src, Tec, Syk, Csk, Fes, Abl, Jak, Fak, Ack, tion for several mutations associated with XLA: mis- Brk, and Srm (Bolen and Brugge, 1997).
    [Show full text]
  • Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia
    Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia Title Page by Ravi K. Patel Bachelor of Science, University of Minnesota, 2013 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2019 Commi ttee Membership Pa UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE Commi ttee Membership Page This dissertation was presented by Ravi K. Patel It was defended on May 31, 2019 and approved by Qiming (Jane) Wang, Associate Professor Pharmacology and Chemical Biology Vaughn S. Cooper, Professor of Microbiology and Molecular Genetics Adrian Lee, Professor of Pharmacology and Chemical Biology Laura Stabile, Research Associate Professor of Pharmacology and Chemical Biology Thomas E. Smithgall, Dissertation Director, Professor and Chair of Microbiology and Molecular Genetics ii Copyright © by Ravi K. Patel 2019 iii Abstract Src-Family Kinases Play an Important Role in Flt3-ITD Acute Myeloid Leukemia Prognosis and Drug Efficacy Ravi K. Patel, PhD University of Pittsburgh, 2019 Abstract Acute myelogenous leukemia (AML) is a disease characterized by undifferentiated bone-marrow progenitor cells dominating the bone marrow. Currently the five-year survival rate for AML patients is 27.4 percent. Meanwhile the standard of care for most AML patients has not changed for nearly 50 years. We now know that AML is a genetically heterogeneous disease and therefore it is unlikely that all AML patients will respond to therapy the same way. Upregulation of protein-tyrosine kinase signaling pathways is one common feature of some AML tumors, offering opportunities for targeted therapy.
    [Show full text]
  • Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
    Published OnlineFirst June 13, 2011; DOI: 10.1158/1078-0432.CCR-10-2616 Clinical Cancer Molecular Pathways Research Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors Juan Carlos Montero1, Samuel Seoane1, Alberto Ocaña2,3, and Atanasio Pandiella1 Abstract Dasatinib is a small molecule tyrosine kinase inhibitor that targets a wide variety of tyrosine kinases implicated in the pathophysiology of several neoplasias. Among the most sensitive dasatinib targets are ABL, the SRC family kinases (SRC, LCK, HCK, FYN, YES, FGR, BLK, LYN, and FRK), and the receptor tyrosine kinases c-KIT, platelet-derived growth factor receptor (PDGFR) a and b, discoidin domain receptor 1 (DDR1), c-FMS, and ephrin receptors. Dasatinib inhibits cell duplication, migration, and invasion, and it triggers apoptosis of tumoral cells. As a consequence, dasatinib reduces tumoral mass and decreases the metastatic dissemination of tumoral cells. Dasatinib also acts on the tumoral microenvironment, which is particularly important in the bone, where dasatinib inhibits osteoclastic activity and favors osteogenesis, exerting a bone-protecting effect. Several preclinical studies have shown that dasatinib potentiates the antitumoral action of various drugs used in the oncology clinic, paving the way for the initiation of clinical trials of dasatinib in combination with standard-of-care treatments for the therapy of various neoplasias. Trials using combinations of dasatinib with ErbB/HER receptor antagonists are being explored in breast, head and neck, and colorectal cancers. In hormone receptor–positive breast cancer, trials using combina- tions of dasatinib with antihormonal therapies are ongoing. Dasatinib combinations with chemother- apeutic agents are also under development in prostate cancer (dasatinib plus docetaxel), melanoma (dasatinib plus dacarbazine), and colorectal cancer (dasatinib plus oxaliplatin plus capecitabine).
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]
  • The Role of SRC Family Kinases in FLT3 Signaling T ⁎ Julhash U
    International Journal of Biochemistry and Cell Biology 107 (2019) 32–37 Contents lists available at ScienceDirect International Journal of Biochemistry and Cell Biology journal homepage: www.elsevier.com/locate/biocel Review article The role of SRC family kinases in FLT3 signaling T ⁎ Julhash U. Kazia,b, Lars Rönnstranda,b,c, a Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden b Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden c Division of Oncology, Skåne University Hospital, Lund, Sweden ARTICLE INFO ABSTRACT Keywords: The receptor tyrosine kinase FLT3 is expressed almost exclusively in the hematopoietic compartment. Binding of FLT3 its ligand, FLT3 ligand (FL), induces dimerization and activation of its intrinsic tyrosine kinase activity. This FLT3 ligand leads to autophosphorylation of FLT3 on several tyrosine residues which constitute high affinity binding sites for Receptor tyrosine kinase signal transduction molecules. Recruitment of these signal transduction molecules to FLT3 leads to the activation Src family kinase of several signal transduction pathways that regulate cell survival, cell proliferation and differentiation. Acute myeloid leukemia Oncogenic, constitutively active mutants of FLT3 are known to be expressed in acute myeloid leukemia and to correlate with poor prognosis. Activation of the receptor mediates cell survival, cell proliferation and differ- entiation of cells. Several of the signal transduction pathways downstream of FLT3 have been shown to include various members of the SRC family of kinases (SFKs). They are involved in regulating the activity of RAS/ERK pathways through the scaffolding protein GAB2 and the adaptor protein SHC. They are also involved in negative regulation of signaling through phosphorylation of the ubiquitin E3 ligase CBL.
    [Show full text]
  • Recent Advances in Pharmacological Diversification of Src Family Kinase Inhibitors Preeya Negi1, Rameshwar S
    Negi et al. Egyptian Journal of Medical Human Genetics (2021) 22:52 Egyptian Journal of Medical https://doi.org/10.1186/s43042-021-00172-x Human Genetics REVIEW Open Access Recent advances in pharmacological diversification of Src family kinase inhibitors Preeya Negi1, Rameshwar S. Cheke2 and Vaishali M. Patil1* Abstract Background: Src kinase, a nonreceptor protein-tyrosine kinase is composed of 11 members (in human) and is involved in a wide variety of essential functions required to sustain cellular homeostasis and survival. Main body of the abstract: Deregulated activity of Src family kinase is related to malignant transformation. In 2001, Food and Drug Administration approved imatinib for the treatment of chronic myeloid leukemia followed by approval of various other inhibitors from this category as effective therapeutics for cancer patients. In the past decade, Src family kinase has been investigated for the treatment of diverse pathologies in addition to cancer. In this regard, we provide a systematic evaluation of Src kinase regarding its mechanistic role in cancer and other diseases. Here we comment on preclinical and clinical success of Src kinase inhibitors in cancer followed by diabetes, hypertension, tuberculosis, and inflammation. Short conclusion: Studies focusing on the diversified role of Src kinase as potential therapeutical target for the development of medicinally active agents might produce significant advances in the management of not only various types of cancer but also other diseases which are in demand for potent and safe therapeutics. Keywords: Src family kinase, Src kinase inhibitors, Anticancer agents, Antidiabetic agents, Antituberculosis agents Background phases namely initiation, promotion, and progression. The group of diseases in which the body cells grow and Benign tumors can rarely become malignant, and the divide uncontrollably is collectively termed as cancer.
    [Show full text]
  • Src Protein-Tyrosine Kinase Structure, Mechanism, and Small Molecule Inhibitors
    Pharmacological Research 94 (2015) 9–25 Contents lists available at ScienceDirect Pharmacological Research j ournal homepage: www.elsevier.com/locate/yphrs Invited Review Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors ∗ Robert Roskoski Jr. Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742-8814, United States a r t i c l e i n f o a b s t r a c t Article history: The physiological Src proto-oncogene is a protein-tyrosine kinase that plays key roles in cell growth, Received 26 January 2015 division, migration, and survival signaling pathways. From the N- to C-terminus, Src contains a unique Accepted 26 January 2015 domain, an SH3 domain, an SH2 domain, a protein-tyrosine kinase domain, and a regulatory tail. The Available online 3 February 2015 chief phosphorylation sites of human Src include an activating pTyr419 that results from phosphory- lation in the kinase domain by an adjacent Src molecule and an inhibitory pTyr530 in the regulatory This paper is dedicated to the memory of tail that results from phosphorylation by C-terminal Src kinase (Csk) or Chk (Csk homologous kinase). Prof. Donald F. Steiner (1930–2014) – advisor, mentor, and discoverer of The oncogenic Rous sarcoma viral protein lacks the equivalent of Tyr530 and is constitutively activated. proinsulin. Inactive Src is stabilized by SH2 and SH3 domains on the rear of the kinase domain where they form an immobilizing and inhibitory clamp. Protein kinases including Src contain hydrophobic regulatory and Chemical compounds studied in this article: catalytic spines and collateral shell residues that are required to assemble the active enzyme.
    [Show full text]
  • Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
    Review Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy Ursula Bommhardt, Burkhart Schraven and Luca Simeoni * Institute of Molecular and Clinical Immunology, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany * Correspondence: [email protected]; Tel. +49-391-6717894 Received: 12 June 2019; Accepted: 12 July 2019; Published: 16 July 2019 Abstract: In recent years, the lymphocyte-specific protein tyrosine kinase (Lck) has emerged as one of the key molecules regulating T-cell functions. Studies using Lck knock-out mice or Lck-deficient T-cell lines have shown that Lck regulates the initiation of TCR signaling, T-cell development, and T-cell homeostasis. Because of the crucial role of Lck in T-cell responses, strategies have been employed to redirect Lck activity to improve the efficacy of chimeric antigen receptors (CARs) and to potentiate T-cell responses in cancer immunotherapy. In addition to the well-studied role of Lck in T cells, evidence has been accumulated suggesting that Lck is also expressed in the brain and in tumor cells, where it actively takes part in signaling processes regulating cellular functions like proliferation, survival and memory. Therefore, Lck has emerged as a novel druggable target molecule for the treatment of cancer and neuronal diseases. In this review, we will focus on these new functions of Lck. Keywords: Lck; T cell; CAR; cancer; leukemia; brain 1. Introduction The lymphocyte-specific protein tyrosine kinase (Lck) is a member of the Src family of protein tyrosine kinases firstly identified in the 1980s [1,2]. Since then, the function of Lck has been extensively investigated and many mechanistic insights into the regulation of its activity have been revealed.
    [Show full text]
  • Phosphorylation Ε CD3 Phosphorylation/ZAP70
    Differential Src Family Kinase Activity Requirements for CD3 ζ Phosphorylation/ZAP70 Recruitment and CD3ε Phosphorylation This information is current as of September 27, 2021. Tara L. Lysechko and Hanne L. Ostergaard J Immunol 2005; 174:7807-7814; ; doi: 10.4049/jimmunol.174.12.7807 http://www.jimmunol.org/content/174/12/7807 Downloaded from References This article cites 38 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/174/12/7807.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Differential Src Family Kinase Activity Requirements for CD3␨ Phosphorylation/ZAP70 Recruitment and CD3⑀ Phosphorylation1 Tara L. Lysechko and Hanne L. Ostergaard2 The current model of T cell activation is that TCR engagement stimulates Src family tyrosine kinases (SFK) to phosphorylate CD3␨.
    [Show full text]
  • Depletion of Csk Preferentially Reduces the Protein Level of Lyna In
    www.nature.com/scientificreports OPEN Depletion of Csk preferentially reduces the protein level of LynA in a Cbl-dependent manner in cancer cells Takahisa Kuga1 ✉ , Yuka Yamane1, Soujirou Hayashi1, Masanari Taniguchi1, Naoto Yamaguchi2 & Nobuyuki Yamagishi1 There are eight human Src-family tyrosine kinases (SFKs). SFK members c-Src, c-Yes, Fyn, and Lyn are expressed in various cancer cells. SFK kinase activity is negatively regulated by Csk tyrosine kinase. Reduced activity of Csk causes aberrant activation of SFKs, which can be degraded by a compensatory mechanism depending on Cbl-family ubiquitin ligases. We herein investigated whether all SFK members are similarly downregulated by Cbl-family ubiquitin ligases in cancer cells lacking Csk activity. We performed Western blotting of multiple cancer cells knocked down for Csk and found that the protein levels of the 56 kDa isoform of Lyn (LynA), 53 kDa isoform of Lyn (LynB), c-Src, and Fyn, but not of c-Yes, were reduced by Csk depletion. Induction of c-Cbl protein levels was also observed in Csk-depleted cells. The reduction of LynA accompanying the depletion of Csk was signifcantly reversed by the knockdown for Cbls, whereas such signifcant recovery of LynB, c-Src, and Fyn was not observed. These results suggested that LynA is selectively downregulated by Cbls in cancer cells lacking Csk activity. Te Src-family tyrosine kinases (SFKs) are composed of eight members in humans: c-Src, c-Yes, Fyn, Lyn, Lck, Fgr, Hck and Blk1. c-Src, c-Yes, Fyn and Lyn are widely expressed in a variety of cell types, whereas other members are primarily restricted to specifc cell types2.
    [Show full text]
  • Cortactin: a Major Cellular Target of the Gastric Carcinogen Helicobacter Pylori
    cancers Review Cortactin: A Major Cellular Target of the Gastric Carcinogen Helicobacter pylori Irshad Sharafutdinov , Steffen Backert and Nicole Tegtmeyer * Division of Microbiology, Department of Biology, Friedrich Alexander University Erlangen-Nuremberg, Staudtstr. 5, D-91058 Erlangen, Germany; [email protected] (I.S.); steff[email protected] (S.B.) * Correspondence: [email protected] Received: 5 December 2019; Accepted: 6 January 2020; Published: 9 January 2020 Abstract: Cortactin is an actin binding protein and actin nucleation promoting factor regulating cytoskeletal rearrangements in nearly all eukaryotic cell types. From this perspective, cortactin poses an attractive target for pathogens to manipulate a given host cell to their own benefit. One of the pathogens following this strategy is Helicobacter pylori, which can cause a variety of gastric diseases and has been shown to be the major risk factor for the onset of gastric cancer. During infection of gastric epithelial cells, H. pylori hijacks the cellular kinase signaling pathways, leading to the disruption of key cell functions. Specifically, by overruling the phosphorylation status of cortactin, H. pylori alternates the activity of molecular interaction partners of this important protein, thereby manipulating the performance of actin-cytoskeletal rearrangements and cell movement. In addition, H. pylori utilizes a unique mechanism to activate focal adhesion kinase, which subsequently prevents host epithelial cells from extensive lifting from the extracellular matrix in order to achieve chronic infection in the human stomach. Keywords: Abl; Src; CagA; cagPAI; FAK; Helicobacter pylori; signaling; type IV secretion; T4SS; tyrosine kinases; SHP2 1. Introduction The human pathogen Helicobacter pylori currently colonizes the stomach of over half of the world’s population.
    [Show full text]